Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study

INTRODUCTION: Adalimumab has been used successfully in the treatment of psoriasis. The objective of the study is to compare the efficacy, safety, and immunogenicity between HLX03, an adalimumab biosimilar, and adalimumab in Chinese patients with moderate-to-severe plaque psoriasis. METHODS: In this...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Lin, Li, Linfeng, Cheng, Hao, Ding, Yangfeng, Biao, Zhenshu, Zhang, Shifa, Geng, Songmei, Liu, Quanzhong, Fang, Hong, Song, Zhiqi, Lu, Yan, Li, Shanshan, Guo, Qing, Tao, Juan, He, Li, Gu, Jun, Yang, Qinping, Han, Xiuping, Gao, Xinghua, Deng, Danqi, Li, Shenqiu, Wang, Qingyu, Zhu, Jun, Zhang, Jianzhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799567/
https://www.ncbi.nlm.nih.gov/pubmed/34816373
http://dx.doi.org/10.1007/s12325-021-01899-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799567/
https://www.ncbi.nlm.nih.gov/pubmed/34816373
http://dx.doi.org/10.1007/s12325-021-01899-0

Ejemplares similares